ARVN News and Press, Arvinas Inc. From 05/25/24

2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...

NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2 clinical trial with vepdegestrant, a novel investigational oral PROteolysis Targeting Chimera (PROTA...

2024-05-16 14:15:01 ET Oppenheimer analyst issues OUTPERFORM recommendation for ARVN on May 16, 2024 01:11PM ET. The previous analyst recommendation was Outperform. ARVN was trading at $32.875 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in combination with palbociclib were consistent with data previously reported at SABCS in December 202...

2024-05-12 11:00:00 ET More on Acadia Pharma, BridgeBio Pharma, etc. ACADIA Pharmaceuticals Inc. (ACAD) Q1 2024 Earnings Call Transcript ACADIA Pharmaceuticals Inc. 2024 Q1 - Results - Earnings Call Presentation Rocket Pharmaceuticals: Cautiously Optimistic (Rating U...

NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress held from May 15-17, ...

2024-05-09 05:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-07 13:54:24 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Arvinas (NASDAQ: ARVN ) just reported results for the first quarter of 2024. Arvinas reported earnings per share of -97 cents. This was above the analyst estimate for EPS ...

2024-05-07 07:28:22 ET More on Arvinas Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation Arvinas: Behind The Huge Rally Arvinas announces CFO Sean Cassidy's departure Citi downgrades Arvinas to neutral, cites valuation...

– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – ...